Brief Communication: Combination of an MIP3α-Antigen Fusion Therapeutic DNA Vaccine With Treatments of IFNα and 5-Aza-2'Deoxycytidine Enhances Activated Effector CD8+ T Cells Expressing CD11c in the B16F10 Melanoma Model

Overview

Journal J Immunother

Specialty Allergy & Immunology

Date 2024 Oct 14

PMID 39397434

Authors

Kaitlyn Fessler

Jiaqi Zhang

Avinaash K Sandhu

Yinan Hui

Aakanksha R Kapoor

Samuel K Ayeh

Styliani Karanika

Petros C Karakousis

Richard B Markham

James T Gordy

Affiliations

Soon will be listed here.

Abstract

Previous studies in the B16F10 mouse melanoma model have demonstrated that combining a DNA vaccine comprised of regions of gp100 and tyrosinase-related protein 2 fused to macrophage-inflammatory protein 3-alpha (MIP3α) with recombinant interferon alpha (IFN) and 5-Aza-2'-deoxycytidine (5Aza) treatments resulted in significantly greater antitumor activity and immunogenicity in the tumor microenvironment (TME). This brief report details that the combination of vaccine with treatments IFN and 5Aza results in an increase in the TME of a distinct CD11c+ CD8+ T-cell population. This cell population correlates with tumor size, is primarily comprised of effector or effector memory T cells, and has a more robust response to ex vivo stimulation as compared with CD11c- CD8+ T cells. In conclusion, this combination therapy results in a greater presence of highly active effector CD8+ T cells expressing CD11c in the TME, which are likely primary contributors to treatment efficacy.

References

Ju S, Park S, Lee S, Kwon B, Kim B . Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody. Mol Cells. 2007; 24(1):132-8. View

Gordy J, Luo K, Kapoor A, Kim E, Ayeh S, Karakousis P . Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-α and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model. Cancer Immunol Immunother. 2020; 69(4):569-580. PMC: 11027820. DOI: 10.1007/s00262-019-02471-0. View

Gordy J, Sandhu A, Fessler K, Luo K, Kapoor A, Ayeh S . IFNα and 5-Aza-2'-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model. Front Immunol. 2023; 13:1074644. PMC: 9892704. DOI: 10.3389/fimmu.2022.1074644. View

Joshi N, Cui W, Chandele A, Lee H, Urso D, Hagman J . Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007; 27(2):281-95. PMC: 2034442. DOI: 10.1016/j.immuni.2007.07.010. View

Beyer M, Wang H, Peters N, Doths S, Koerner-Rettberg C, Openshaw P . The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. Respir Res. 2005; 6:70. PMC: 1184101. DOI: 10.1186/1465-9921-6-70. View

Vinay D, Kwon B . CD11c+CD8+ T cells: two-faced adaptive immune regulators. Cell Immunol. 2010; 264(1):18-22. DOI: 10.1016/j.cellimm.2010.05.010. View

Weir G, Liwski R, Mansour M . Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers (Basel). 2013; 3(3):3114-42. PMC: 3759189. DOI: 10.3390/cancers3033114. View

Gordy J, Luo K, Zhang H, Biragyn A, Markham R . Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model. J Immunother Cancer. 2016; 4:96. PMC: 5168589. DOI: 10.1186/s40425-016-0189-y. View

Schiavo R, Baatar D, Olkhanud P, Indig F, Restifo N, Taub D . Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood. 2006; 107(12):4597-605. PMC: 1895803. DOI: 10.1182/blood-2005-08-3207. View

10.

Gordy J, Luo K, Francica B, Drake C, Markham R . Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons. J Immunother. 2018; 41(4):181-189. PMC: 5891382. DOI: 10.1097/CJI.0000000000000212. View

11.

Patel P, Ottensmeier C, Mulatero C, Lorigan P, Plummer R, Pandha H . Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. Oncoimmunology. 2018; 7(6):e1433516. PMC: 5980353. DOI: 10.1080/2162402X.2018.1433516. View

12.

Kim Y, Seo S, Choi B, Kang W, Kim C, Lee S . 4-1BB costimulation enhances HSV-1-specific CD8+ T cell responses by the induction of CD11c+CD8+ T cells. Cell Immunol. 2006; 238(2):76-86. DOI: 10.1016/j.cellimm.2006.01.004. View

13.

Takeda Y, Azuma M, Matsumoto M, Seya T . Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy. J Exp Clin Cancer Res. 2016; 35(1):143. PMC: 5020536. DOI: 10.1186/s13046-016-0416-x. View

14.

Biragyn A, Ruffini P, Coscia M, Harvey L, Neelapu S, Baskar S . Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood. 2004; 104(7):1961-9. DOI: 10.1182/blood-2004-02-0637. View

15.

Saoulli K, Lee S, Cannons J, Yeh W, Santana A, Goldstein M . CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med. 1998; 187(11):1849-62. PMC: 2212301. DOI: 10.1084/jem.187.11.1849. View